Details for Patent: 7,235,576
✉ Email this page to a colleague
Summary for Patent: 7,235,576
Title: | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Abstract: | This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. |
Inventor(s): | Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy B. (Nishinomiya, JP), Scott; William J. (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert N. (North Haven, CT) |
Assignee: | Bayer Pharmaceuticals Corporation (West Haven, CT) |
Application Number: | 10/042,203 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,235,576 |
Patent Claim Types: see list of patent claims | Compound; Use; |
Drugs Protected by US Patent 7,235,576
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |